Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Umasankar Ramadoss (NPI 1962499806)

Field	Value
Entity Type	Individual
Organization	Umasankar Ramadoss
Address	1705 E Broadway
City	Columbia
State	MO
ZIP	65201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 5, 2005

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider’s Medicare revenue is highly concentrated: the precomputed top three Medicare codes account for 60.7% of total Medicare revenue, with J9271 (pembrolizumab) at $1.3M (39.8% of Medicare revenue, 29.2K claims), J9299 (nivolumab) at $349.9K (11.1%, 14.6K claims), and J0897 (denosumab) at $311K (9.9%, 17.3K claims). Those three line items together dominate the payer mix on the Medicare side and are the primary drivers of the $3.3M in reported Medicare revenue.

The code mix and descriptions indicate a medical oncology infusion practice focused on immunotherapy and supportive oncology care: high-volume use of checkpoint inhibitors (J9271 and J9299), bone-health management with denosumab (J0897), and additional oncology therapeutics such as daratumumab (J9144) and atezolizumab (J9022). Procedural chemotherapy administration codes (e.g., 96413, 96365, 96417) and imaging (78815, 74177) further support an integrated ambulatory infusion and treatment workflow rather than a purely procedural or surgical practice.

Payer concentration is effectively single-payer Medicare: this profile shows $3.3M in total Medicare revenue and no Medicaid billing on file. The absence of Medicaid activity means the provider’s outpatient oncology business is almost entirely Medicare-exposed, which concentrates reimbursement risk and network access considerations on the Medicare market in Missouri.

Competitive standing is mixed across drugs: for pembrolizumab (J9271) the provider ranks #133 of 1841 (93th percentile; notably above typical national volume for this code), signaling it is a major national user of this agent. By contrast, nivolumab (J9299) sits at #260 of 505 (49th percentile; typical, unremarkable volume for this code), indicating routine participation for that drug rather than market leadership.

Several codes are statistical outliers on utilization compared with national peers: 99214 E/M visits show 1.5K claims and $136.5K revenue (4.3% of Medicare revenue) and rank #3591 of 479517 (99th percentile; extreme outlier, far above typical national volume), implying unusually high ambulatory follow-up or complex visit volume for an oncology practice. Other high-percentile codes include 96413 (627 claims, $56.4K, ranks #375 of 7514, 95th percentile; notably above typical national volume) and J0881 darbepoetin (55.6K claims, $111.1K, ranks #48 of 1114, 96th percentile; notably above typical national volume), which together point to above-average chemotherapy administration and supportive-care throughput.

High claim counts with relatively low average paid-per-claim on several J-codes suggest revenue is driven by unit volume rather than high per-claim reimbursement: J9271 shows 29.2K claims at $43 avg paid/claim, J9299 14.6K claims at $24 avg paid/claim, and J0897 17.3K claims at $18 avg paid/claim. This pattern is consistent with mg- or unit-based J-code billing for high-volume biologic and immunotherapy agents in an infusion setting.

The broader procedural and infusion footprint is reinforced by supportive and add-on administration codes: notable activity in 96367 (380 claims, $8K, ranks #663 of 4032, 84th percentile; typical, unremarkable volume), 96417 (168 claims, $7.7K, ranks #374 of 3014, 87th percentile; typical, unremarkable volume), and 96365 (183 claims, $7.7K, ranks #1971 of 8873, 78th percentile; typical, unremarkable volume). Together these entries underline consistent chemotherapy administration operations and aftercare infusions common to outpatient oncology centers.

The provider’s NPI has been enumerated since 2005-10-05 (~21 years ago), indicating a long-tenured practice presence. This tenure, combined with high utilization of office visits (99214/99213) and infusion codes, suggests an established referral base and an operationally mature ambulatory oncology service line.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

71 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	29,200	$40	$1.3M
J9299	Injection, nivolumab, 1 mg	14,580	$20	$349.9K
J0897	Injection, denosumab, 1 mg	17,280	$20	$311K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,660	$40	$253.1K
J9022	Injection, atezolizumab, 10 mg	3,240	$60	$207.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,500	$90	$136.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	55,550	$1	$111.1K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,550	$30	$84.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	70	$1,030	$71.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$90	$56.4K

Showing 1–10 of 71

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 71 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Umasankar Ramadoss — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

71 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	40	9,100	$40	$502K
J9299	11	20	14,170	$20	$360.3K
J9144	15	20	7,200	$40	$308.4K
J9022	1	10	3,240	$60	$207.3K
J1568	5	10	2,900	$30	$103.8K
J0897	10	210	2,400	$20	$82.4K
J0881	3	10	15,500	$1	$63.1K
Q5119	9	10	1,570	$20	$43.6K
J1437	5	10	2,500	$20	$43.5K
J0641	3	10	35,150	$1	$27.3K

Showing 1–10 of 71

Related Providers

Other providers that share a Tax Identification Number (TIN) with Umasankar Ramadoss, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Liana Makarian	MO	Hematology & Oncology Physician	$3.3M	$0
Mark Tungesvik	MO	Hematology & Oncology Physician	$3.3M	$0
Elangovan Balakrishnan	MO	Hematology & Oncology Physician	$3.1M	$0
Andrew Iliff	MO	Hematology & Oncology Physician	$2.8M	$0
Mark Bryer	MO	Radiation Oncology Physician	$638K	$0
Reed Cope	MO	Radiation Oncology Physician	$572.2K	$0
Alexandre Tungesvik	MO	Hematology & Oncology Physician	$569.8K	$0
Harold Johnson	MO	Radiation Oncology Physician	$542.5K	$0
Hunter Nolen	MO	Urology Physician	$359.5K	$0
Andrew Leiker	MO	Radiation Oncology Physician	$303.9K	$0

Nearby Providers

Other providers in the same ZIP code as Umasankar Ramadoss, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Woodhaven	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$88.3M
Palmer's Home Care, LLC	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$82.3M
Oats, Inc.	MO	Non-emergency Medical Transport (VAN)	$0	$23.4M
Independent Living Center Of Mid-missouri Inc.	MO	Specialist	$0	$14.2M
Ch Allied Services, Inc.	MO	General Acute Care Hospital	$0	$8.6M
Central Missouri Area Agency On Aging	MO	Voluntary or Charitable Agency	$0	$8.4M
Life Christain Outreach	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$7.1M
Surgical Center At Columbia Orthopaedic Group LLC	MO	Ambulatory Surgical Clinic/Center	$6.2M	$0
Mid-missouri Supported Living	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$5.3M
Woodhaven Learning Center	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$5.1M

Umasankar Ramadoss — Billing Profile & Reimbursement Data

Sign up for Umasankar Ramadoss — Billing Profile & Reimbursement Data policy alerts

Umasankar Ramadoss — Billing Profile & Reimbursement Data

Sign up for Umasankar Ramadoss — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References